Curated News
By: NewsRamp Editorial Staff
April 04, 2024
Nexalin Technology Unveils Positive Results of Clinical Study for Gen-2 tACS Device
Discuss on Reddit
Substack
GithubTLDR
- Nexalin's Gen-2 tACS device shows positive results in reducing pain for veteran patients with mTBI, tapping into a $7.2 billion market potential.
- The clinical study at UC San Diego involved a randomized, double-blind, placebo-controlled study with 24 veteran patients receiving active or sham tACS over eight weeks.
- Nexalin's innovative approach offers promise in improving the quality of life for individuals suffering from mTBI, providing hope for effective treatment options in the future.
- The positive results from the clinical study offer hope for better treatment options for individuals with mTBI, addressing a significant concern for veterans and the general public.
Impact - Why it Matters
The positive results from this study offer hope for individuals suffering from mTBI, potentially improving their quality of life and providing effective treatment options in the future. The innovative approach by Nexalin Technology could significantly impact the traumatic brain injuries assessment market, which is projected to reach over $7.2 billion by 2032.
Summary
Nexalin Technology CEO Mark White shared positive results from a clinical study evaluating Nexalin’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study, conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs, showed promising outcomes. The innovative approach offers hope for effective treatment options in the future.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Nexalin Technology Unveils Positive Results of Clinical Study for Gen-2 tACS Device
